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Introduction
Prothrombin complex concentrates (PCCs) were origi-
nally developed as a source of factor IX for the treatment 
of patients with haemophilia B [1]. Subse quently, PCCs 
were used in the treatment of bleeding in haemophilia 
patients with inhibitors [1]. Th ese concen trates have 
largely been superseded in this setting by high-purity, 
plasma-derived factor IX and, more recently, recom-
binant factor IX and bypassing agents such as activated 
PCC and recombinant activated factor VII.
Today, PCCs are mainly used for the emergency 
reversal of oral vitamin K antagonist (VKA) therapy [2,3], 
although in the USA they are only approved for haemo-
philia. Bleeding is the most frequent complication of oral 
anticoagulation, causing considerable morbidity and 
mortality [4]. Emergency reversal of anticoagulation is 
most commonly needed to control bleeding as quickly as 
possible. Th e use of PCCs has also been proposed in 
severe liver disease and in perioperative and trauma-
related bleeding [5-8], although fewer studies have been 
performed in these settings than for anticoagulation 
reversal.
Most commercially available PCCs contain four 
vitamin K-dependent coagulation factors (II, VII, IX and 
X), although not all contain factor VII (Table 1). A recent 
study of PCC constituents found broad correlation with 
the products’ labelled values [9]. In most currently 
available PCCs, the factors are found in the inactivated 
form. In addition to the coagulation factors, many of 
today’s PCCs include one or more of the following 
coagulation inhibitors: heparin, antithrombin, protein C, 
protein S and protein Z.
In settings where rapid correction of coagulopathy is 
required, such as in cases of intracranial haemorrhage 
[10], PCCs may off er some advantages over fresh frozen 
plasma (FFP), the traditionally established therapy. For 
reasons such as reduced volume, room-temperature 
storage and lack of requirement for blood type matching, 
the total time for administration is much reduced with 
PCCs compared with FFP. Furthermore, most currently 
available PCCs are subjected to at least one viral in acti-
vation step (Table 1), which reduces the risk of pathogen 
transmission. Also, as PCCs are free of leukocytes and 
some are also nanofi ltrated, they are unlikely to provoke 
transfusion-related acute lung injury.
Historically, the major drawback of PCCs has been the 
risk of thrombotic complications [11]. Today’s PCCs 
diff er considerably from the preparations used to treat 
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haemophiliacs in the 1970s and 1980s, and in general the 
risk of thrombosis with PCCs appears to have been 
reduced. Nevertheless, accurate risk–benefi t assessments 
of PCC therapy are dependent on thorough under-
standing of the potential for thrombogenicity. Th e aims 
of the present review are to provide a systematic overview 
of thrombotic complications reported with PCCs, to 
examine the possible pathogenesis of thrombotic events, 
and to discuss safety precautions and means to reduce 
thrombotic complications. Furthermore, the review 
performs a critical comparison of PCC with FFP.
Literature search strategy
We used the PUBMED database to search for publi-
cations with ‘complex concentrate(s)’ or ‘coagulation 
factor concentrate(s)’ as key words, plus additional terms 
including ‘anticoagulation reversal’ and ‘over-anticoagu-
la tion’. Citations were selected from articles published in 
English between 1988 and 2010.
Thrombotic complications with PCCs
Th rombotic complications associated with PCCs include 
venous thromboembolism, disseminated intravascular 
coagulation (DIC), microvascular thrombosis and 
myocardial infarction [1]. An overview of studies that 
have reported such complications is presented in Table 2. 
Th e risk of thrombotic complications occurring with 
PCCs or other procoagulant haemostatic interventions 
must be considered in the context of any underlying 
disease and the patient’s clinical condition at the time of 
PCC administration [12].
Haemophilia
Prior to the introduction of high-purity, plasma-derived 
factor IX, haemophilia B patients were treated with 
PCCs. As haemophilia B patients are defi cient in factor 
IX only, administration of PCC will produce supra-
physiological levels of the other factors in the preparation – 
this, coupled with the need for repetitive dosing in 
haemophilia B, can increase patients’ risk of thrombosis. 
Since the introduction of PCCs for haemo philia in the 
1960s, complications such as deep vein thrombosis, DIC 
and pulmonary embolism have been reported. In a 
survey of 150 physicians in several coun tries, 72 
thrombotic complications occurring between 1987 and 
1990 were reported [11]. An increased risk of adverse 
eff ects was seen in patients with large muscle haema-
tomas, immobilisation and orthopaedic surgery. In these 
conditions, treatment involves administration of large, 
repeated doses of PCCs [11]. In the 1980s, several cases 
of acute myocardial infarction in young haemo philiacs 
with inhibitors were reported; many of these patients had 
received large, repeated doses of PCCs [13].
Anticoagulation reversal
All patients receiving VKA therapy have underlying 
thrombotic risk factors, which may be unmasked when 
anticoagulation is reversed. A review of 14 studies each 
Table 1. Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates
 International units relative to factor IX
  Factor Factor Factor Factor  Additional
Brand name Manufacturer II VII IX X Viral inactivation information
Bebulin VH Baxter BioScience,  120 (13) 100 100 Vapour heat, 60°C for 10 hours at 190 mbar, Heparin added
 Austria      then 80°C for 1 hour at 375 mbar
Beriplex P/N CSL Behring,  128 68 100 152 Pasteurisation at 60°C for 10 hours, and  Protein C; 
 Germany     nanofi ltration antithrombin, heparin 
       and albumin added
Cofact Sanquin,  56-140 28-80 100 56-140 Solvent/detergent and 15 nm Antithrombin added
 the Netherlands     nanofi ltration
KASKADIL LFB, France 148 40 100 160 Solvent/detergent Heparin added
Octaplex Octapharma, Austria  44-152 36-96 100 50 Solvent/detergent and nanofi ltration Heparin added; low
 and France       activated factor VII 
       content
Profi lnine SD Grifols, USA 148 (11) 100 64 Solvent/detergent –
Prothrombinex VF CSL Bioplasma,  100 (–) 100 100 Dry heat, 80°C for 72 hours and –
 Australia     nanofi ltration
Prothromplex T Baxter BioScience,  100 85 100 100 Vapour heat, 60°C for 10 hours at 190 mbar, Antithrombin and
 Austria      then 80°C for 1 hour at 375 mbar heparin added
UMAN Complex D.I. Kedrion, Italy 100 (–) 100 80 Solvent/detergent and dry heat, 100°C for  Antithrombin and
      30 minutes heparin added
Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding 
concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. 
Factor VII presented in parentheses for three-factor PCCs.
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involving at least 10 patients (a total of 460 patients) in 
which PCCs were administered for anticoagulation 
reversal revealed no evidence of DIC [14]. Th ere were, 
however, seven thrombotic complications (that is, 1.5% of 
patients experienced a thrombotic event). Four of these, 
two deep vein thromboses and two non-ST elevation 
myocardial infarctions which were identifi ed in a retro-
spective review of 58 patients, were not attributed to 
PCC therapy [15]. Two throm botic strokes occurred in 
patients with extensive co-morbidities [16]. Th e fi rst 
patient, a 75-year-old male, suff ered from multi-infarct 
brain damage, longstanding hypertension, atrial fi bril la-
tion and vascular disease of the legs. Th e other patient 
was an 86-year-old female with atrial fi brillation and a 
large haematoma in the left leg. Finally, a patient with 
peripheral vascular disease, sepsis and renal and cardiac 
failure died of a thrombotic stroke 48 hours after PCC 
treatment, following leg ampu tation [17].
Th ree further thrombotic complications associated 
with PCC use have been identifi ed in articles published 
since Leissinger and colleagues’ review [14]. A study of 
PCC use in 43 patients requiring emergency reversal of 
VKA therapy was published more recently [18]. One 
serious adverse event, suspected pulmonary embolism 
leading to the death of a patient, was considered possibly 
related to study treatment. Th is patient had an underlying 
risk of thrombosis relating to metastatic gastrointestinal 
cancer and atrial fi brillation. In a recent case report, a 
patient receiving PCC for anticoagulant reversal suff ered 
a fatal myocardial infarction [19]. Myocardial infarction 
is a fre quent perioperative complication in the absence of 
PCC treatment and no defi nite causal link with PCC 
adminis tration could be established in this case. 
Furthermore, the patient may have had DIC related to 
abdominal sepsis. A second case report, published by 
Warren and Simon, involved a patient who received 
treatment with PCC and subsequently suff ered massive, 
fatal intracardial throm bosis [20]. Although the authors 
suggest this may have been a complication of PCC 
treatment, there were several important underlying risk 
factors. Th e patient had a history of ischaemic stroke and 
deep venous thrombosis. Th e International Normalised 
Table 2. Studies reporting thrombogenic complications associated with the use of PCCs
    Number of
  PCC Number of thrombotic  
Publication Study type indication patients complications Nature of complications Notes
Lusher [11] Physician survey  Haemophilia Not available 72 (reported Various (for example, deep Increased risk among patients
 and registry  (150 physicians  over a venous thrombosis of the receiving large, repeated
   surveyed) 4-year period) leg, pulmonary embolus, DIC) doses of PCC
Lankiewicz and Retrospective Warfarin reversal 58 4 Deep vein thrombosis (n = 2), Thrombotic complications
colleagues [15] review    non-ST elevation myocardial  were not attributable to PCC
     infarction (n = 2) therapy
van Aart and  Prospective,  Oral anticoagulation 93 2 Thrombotic stroke (n = 2) Both patients were elderly and
colleagues [16] randomised  reversal    had atrial fi brillation; one had
 controlled trial (acenocoumarol or     vascular disease and the other
  phenprocoumon)    had a large haematoma
Preston and  Prospective,  Warfarin reversal 42 1 Thrombotic stroke Stroke occurred following leg
colleagues [17] uncontrolled     amputation, 48 hours after 
 trial     PCC treatment. Patient had 
      peripheral vascular disease
Pabinger- Prospective,  Oral anticoagulation 43 1 Suspected pulmonary Patient had risk of thrombosis
Fasching and  uncontrolled reversal (vitamin K   embolism (fatal) due to metastatic
colleagues  trial antagonists)    gastrointestinal cancer and 
[18,55]      atrial fi brillation
Bagot and  Case report Warfarin reversal 1 1 Myocardial infarction (fatal) No defi nite causal link with 
colleagues [19]      PCC administration; patient 
      may have had DIC related to 
      abdominal sepsis
Warren and  Case report Warfarin reversal 1 1 Intracardial thrombosis (fatal) Patient had a history of 
Simon [20]      ischaemic stroke and deep 
      venous thrombosis; general 
      disturbance of coagulation
Kohler and  Case reports Perioperative setting, 5 5 Thrombotic events (fatal) All patients received an old 
colleagues [22] (n = 5) acquired defi ciencies     PCC that was withdrawn in
  of coagulation factors     1994; all patients had 
      underlying diseases 
      predisposing them to 
      thrombosis or DIC
DIC, disseminated intravascular coagulation; PCC, prothrombin complex concentrate.
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Ratio was extremely high (12.8) and the partial thrombo-
plastin time was elongated, suggesting very low levels of 
prothrombin, factor VII  and protein C; levels of liver 
enzymes were also high. Th ese factors indicate general 
disturbance of coagu lation independent of PCC adminis-
tration. Furthermore, serum potassium was at a level high 
enough to potentially cause cardiac arrest, and the patient’s 
creatinine level (5.2 mg/dl) indicates renal failure.
In all of these cases, therefore, the patients receiving 
PCCs had increased risk of thrombosis due to medical 
history or current illness. As this refl ects the usual 
context of PCC administration, a small number of 
compli cations may be expected. Th e possibility that PCC 
administration has some infl uence over the risk cannot 
be excluded. In most recent cases in the literature, 
however, it seems unlikely that PCC alone was the cause.
Perioperative and trauma-related bleeding
During the past decade, there have been several reports 
of PCC therapy for critical bleeding. Th e aim of this 
approach is to correct critically reduced thrombin 
generation, resulting from major blood loss, consumption 
of coagulation factors and volume administration (this 
excludes patients requiring anticoagulation reversal or 
with a procoagulant status and prophylactic use of PCCs). 
Although there have been few authoritative studies of 
PCCs in this setting, the clinical practice has been used in 
European countries such as Austria, Germany and Swit-
zer land in cases with increased bleeding and prolonged 
initiation of coagulation as measured by viscoelastic 
techniques [21]. Recently published Austrian expert 
opinion consensus recommendations advocate adminis-
tration of PCC (20 to 30 IU/kg bodyweight) in the case of 
persistent bleeding and prolonged clotting time [6]. 
Adequate substitution of fi brinogen was also recom-
mended, prior to administration of PCC.
Regarding the possible complications associated with 
accelerating thrombin generation by administration of 
PCC in the perioperative setting, a cluster of fi ve fatal 
PCC-related thrombotic events in German patients 
under going surgery was reported in the 1990s [22]. None 
of these cases may be considered classical perioperative 
PCC use: two patients required anticoagulation reversal, 
two patients had procoagulant states (including sepsis, 
DIC or high levels of platelets and fi brinogen), and one 
patient received PCC prophylactically (that is, without 
clinical signs of bleeding). All fi ve patients were treated 
with an old PCC that was withdrawn from the market in 
1994 as a result of three of the fatalities [22]. Compared 
with other PCCs available at the time, the withdrawn 
product had high levels of factors II and X and activated 
factor VII, low levels of protein S, and no free 
antithrombin activity, although heparin levels were 
relatively high [22,23]. Co-administration of aprotinin 
was also identi fi ed as playing a possible role in three of 
the cases [22]. More recently, there have been no reports 
of thrombotic complications with PCCs in the treatment 
of perioperative or trauma-related bleeding, although 
only a few studies have been published in these settings 
[8,24,25].
PCCs and thrombotic risk: pathogenesis
Th e potential causes of thrombogenic complications after 
PCC administration remain a subject for debate. Early 
studies in animal models implicated activated factor IX or 
the presence of procoagulant phospholipids as poten tial 
thrombogenic determinants in PCCs [26,27]. A reduc tion 
in thromboembolic complications among haemo philia B 
patients was observed when highly-purifi ed factor IX 
began to replace PCCs. However, direct measure ment of 
activated factor IX revealed that there tended to be higher 
levels in highly-purifi ed factor IX preparations than in 
PCCs [28], suggesting that levels of activated factor IX do 
not correlate with thrombogenicity.
An in vitro model of thrombogenicity has been used 
recently to systematically examine which components of 
PCCs contribute to thrombogenicity [29]. Zymogen 
overload, of prothrombin in particular, was implicated in 
this study as the main mechanism for the thrombogenic 
potential of PCCs. Other studies have also cited pro-
thrombin as the major determinant of excessive thrombin 
generation in an activated PCC preparation [30].
Th e need for balance between procoagulants and anti-
coagulants was suggested by a recent in vitro study of 
thrombin generation in blood from patients with liver 
cirrhosis [31]. Th e authors suggest that haemostasis is 
preserved in these patients because the reduction of 
procoagulants (factor II) is balanced by reduced levels of 
the coagulation inhibitor protein C.
Two studies, using diff erent methodologies, have 
shown that increased levels of factors VII, IX and X did 
not infl uence total thrombin generation [32,33]. In con-
trast, there is a linear relationship between increasing 
levels of factor II and increased thrombin generation 
[32,33]. Finally, a recently published study has shown 
that, following activation with a high concentration of 
tissue factor, prothrombin is amongst the main deter mi-
nants of total thrombin generation [34]. Th e available 
evidence therefore indicates that accumulation of factor 
II could be the primary determinant of thrombotic risk 
associated with frequent doses of PCC. Th e half-lives of 
the coagulation factors diff er considerably, with factors II 
and X having the longest half-lives of the factors 
administered in PCC (60 and 30 hours, respectively, 
compared with 6 hours for factor VII and 20 hours for 
factor IX) [35]. As a consequence, repeated dosing will 
lead to an accumulation of factors II and X as illustrated 
in Figure 1.
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Overall, there remains some uncertainty as to which 
component(s) of PCCs is the leading cause of thrombo-
genicity, but there is accumulating evidence for the 
impor tance of factor II and the balance between this 
coagulation factor and coagulation inhibitors.
Diff erences between today’s PCCs and older 
products
Today’s PCCs have improved safety compared with those 
used in the 1970s and 1980s [12]. Th is improvement is 
probably related to the inclusion of coagulation inhibitors 
such as heparin, antithrombin, protein C, protein S and 
protein Z. Th ese constituents may be speculated to 
provide some balance to the eff ects of the coagulation 
factors, the aims being to avoid excessive increase in 
thrombin generation and to reduce thrombotic risk. Th e 
inclusion of coagulation inhibitors is consistent with 
recommendations to administer early PCCs together 
with heparin and antithrombin [11].
Th e eff ects of one currently available PCC (Beriplex P/N; 
CSL Behring, Marburg, Germany) have been studied in 
healthy volunteers (n = 15) [36]. Considerable increases 
in coagulation factor levels were observed, and these 
were accompanied by increases in plasma concentrations 
of proteins C and S. Importantly, there was no clinical 
evidence of thrombosis, and no increase in the 
thrombogenicity marker D-dimer [36].
In a recent study, the biochemical composition of seven 
commercially available PCCs was measured. With one 
exception – Uman Complex (Kedrion, Castelvecchio 
Pascoli, Italy), which contained negligible factor VII – 
coagulation factor levels were broadly similar in all seven 
products, and all tested negative for activated coagulation 
factors [9]. Th ere were, however, some diff erences in 
coagu lation inhibitor levels (Figure 2), resulting in diff er ent 
thrombin inhibitory capacities. Th ere were also con-
siderable purity diff er ences between the products. It is 
noteworthy that all of the PCCs contained considerable 
concentrations of pro thrombin (factor II), and that S-TIM 
4 or Prothromplex (Baxter, Vienna, Austria) had a higher 
factor II:factor IX ratio than the other products [9].
Pharmacovigilance data for some of the currently 
available PCCs (Table 3) demonstrate that, although 
millions of units have been administered to thousands of 
patients, there have been no proven cases of infection 
transmission, heparin-induced thrombocytopaenia or 
thromboembolism.
One may question how the safety profi le of today’s 
three-factor PCCs compares with that of the four-factor 
products. Unfortunately no comparator trials have been 
performed, so there are no defi nitive answers. Given the 
apparent importance of factor II in thrombotic risk, and 
the fact that the key diff erence between the two types of 
PCC is the presence or absence of factor VII, no major 
inherent diff erences may be expected. Th ree-factor PCCs 
have been reported as suboptimal for warfarin reversal, 
owing to the absence of factor VII [37]. Th us. it has been 
recommended that four-factor PCCs are probably 
preferable to three-factor PCCs or FFP, for acute reversal 
of oral VKAs [38].
Comparing PCCs with human plasma
Th e primary alternative to PCCs – particularly for 
anticoagulant reversal, but also for treatment of acquired 
coagulopathy in the perioperative setting – is human 
plasma. Th rombotic complications with human plasma 
Figure 1. Coagulation factors accumulate diff erently when a prothrombin complex concentrate is administered repeatedly. Illustration of 
how coagulation factors accumulate diff erently when a prothrombin complex concentrate (PCC) is administered repeatedly due to their diff erent 
half-lives. The example shows the theoretical accumulation of factors in plasma sampled immediately after dosing when 40 units/kg four-factor 
PCC is given every 12 hours to a 70 kg patient.
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are rare, which could be cited as an advantage versus 
PCCs. However, there are major drawbacks with human 
plasma versus PCCs. Firstly, a considerably longer time is 
taken to reach haemostasis with human plasma. Before it 
can be administered, compatibility testing is required and 
the human plasma must be thawed and warmed. Th e low 
concentration of coagulation factors in normal human 
plasma means that a large volume may be required to 
deliver enough of the factors to achieve eff ective 
haemostasis. As well as the risk of volume overload, this 
results in an extended administration time. Hence, the 
time taken for preparation and administration of human 
plasma is typically 1 or 2 hours. In contrast, PCCs can be 
administered immediately and a lower volume is required; 
an important consideration when the rapid reversal of 
anticoagulant therapy may be life-saving.
Human plasma transfusion is associated with other 
potential adverse reactions, including transfusion-related 
acute lung injury and allergic reaction [39]. FFP is also 
associated with a risk of allergic reactions, such as skin 
rash, pruritus, urticaria, bronchospasm, angioedema and 
anaphylactic shock [40]. Studies have shown that infusion 
of FFP is associated with increased risk and frequency of 
hospital-acquired infections [41], and that there is a small 
potential risk of disease transmission with human plasma 
[5]. In contrast, PCC manufacture includes at least one 
step of viral reduction or elimination, which minimises 
the risk of transmitting infectious agents.
It is discouraging, faced with the potential side-eff ects 
of FFP, that available data on the effi  cacy of FFP are scarce 
[42,43]. Several studies comparing the effi  cacy of PCCs 
with human plasma for emergency oral anticoagulant 
Figure 2. Coagulation inhibitor levels of diff erent prothrombin complex concentrates. Protein C, protein S and protein Z contents of diff erent 
prothrombin complex concentrates (PCCs) [9].
Table 3. Pharmacovigilance data for some of the commercially available PCCs
    Number of  Number of 
  Amount Estimated cases of Number of cases of 
Brand name Dates of produced number of proven infection cases of proven 
(manufacturer) survey to date applications transmission HIT type II thromboembolism
Beriplex P/N  1996 to 2004 >400 million >200,000  0 0 0 (two cases were reported
(CSL Behring,   units (average dose   but PCC not established as 
Germany)   2,000 units)   the cause)
Cofact  1997 to 2006 ~97 million  ~64,000 to 82,500  0 0 0
(Sanquin,   units (average dose
The Netherlands)   20 to 50 ml)
Uman  2005 to 2007 ~31.5 million  ~16,000  0 0 0
Complex D.I.   units (average dose
(Kedrion, Italy)   2,000 units)
Pharmacovigilance data for some of the commercially available prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of 
clotting factor concentrates, excluding those for national markets only [54]. HIT, heparin-induced thrombocytopaenia.
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reversal have shown that PCCs provide more eff ective 
and more rapid correction of coagulopathy [44-47]. 
Th ese fi ndings, together with the improved safety profi le 
of today’s PCCs, suggest that PCCs should be considered 
preferable to FFP for emergency oral anticoagulant 
reversal. Th is is refl ected in the latest British and 
American guidelines on the reversal of anticoagulation as 
well as other review articles [2,3,14,38].
Possible means of reducing thrombotic risk
As PCCs were originally designed for the treatment of 
haemophilia B, their labelling, and thus dosage, is based 
on the concentration of factor IX. When PCCs are used 
for VKA reversal, it is important to recognise that 
warfarin reduces the levels of the vitamin K-dependent 
coagulation factors to varying degrees, with factor IX 
remaining at 40 to 50% of normal levels, factor VII at 
around 30% of normal, prothrombin at 20% of normal 
and factor X is usually lowest at around 10% of normal 
[48]. As a result, it is diffi  cult to defi ne the optimal ratio 
of factors in a PCC. Care should be taken, however, to 
avoid excessive substitution with prothrombin, particu-
larly during repetitive administration of PCCs when 
prothrombin levels can accumulate because of its long 
half-life. Co-administration of vitamin K is recommended 
when PCCs are used for anticoagulation reversal [2]. 
Vitamin K has a slow onset of action, and the reason for 
its use is to facilitate hepatic production of coagulation 
factors after the constituents of the PCC infusion have 
been metabolised. By reducing the need for repeat 
administration of PCC, co-adminis tration of vitamin K is 
one way of reducing thrombotic risk.
Although the primary purpose of PCCs is the 
restoration of coagulation factors, it is also important to 
consider levels of coagulation inhibitors. VKA therapy 
reduces levels of protein C, protein S and protein Z as 
well as the coagulation factors, and the concentration of 
circulating coagulation inhibitors will be reduced in 
dilutional coagulopathy. Furthermore, chronic liver 
disease – which was identifi ed as a risk factor for throm-
botic complications in haemophilia patients treated with 
earlier formulations of PCCs [12] – frequently causes a 
reduction in the production of antithrombin as well as 
coagulation factors [49]. To avoid thrombotic compli-
cations, monitoring of antithrombin activity and co-
administration of antithrombin concentrate should be 
considered when administering PCCs to patients with 
severe liver disease [5]. Patients with low levels of 
endogenous anti thrombin are likely to be at increased 
risk of thrombosis. Th ere is, therefore, a strong rationale 
for the inclusion of coagulation inhibitors such as protein 
C, protein S and protein Z or antithrombin in PCCs [50].
Accurate bedside monitoring of a patient’s coagulation 
status may provide a means for reducing thrombotic risk. 
Conventional coagulation tests such as the prothrombin 
time are not aff ected by levels of coagulation inhibitors 
such as protein C; the International Normalised Ratio 
may therefore not be a true refl ection of the haemostatic 
state of a patient [31]. During volume replacement of 
blood loss, particularly with colloids, conventional 
prothrombin time and activated partial thromboplastin 
time assays may suggest critical reduction in coagulation 
factors, whereas the coagulation time measured in whole 
blood using thrombo elasto graphy may remain within the 
normal range [51]. Th eoretically, thrombin generation 
measurement should be preferable for guiding PCC 
administration and monitoring its effi  cacy. Th is analysis 
is not yet routine in all laboratories, but thromboelasto-
graphy provides a surrogate estimate of thrombin genera-
tion in whole blood [52,53].
Ultimately, it is incumbent upon physicians to seek 
suffi  cient restoration of thrombin generation to achieve 
haemostasis. Normalisation may not be needed and may 
unmask an underlying predisposition of thrombo embo-
lism. An excessive increase in thrombin generation 
should thus be avoided. Caution must be exercised, and 
PCCs are generally not recommended for use in patients 
at very high risk of thrombosis, such as those with clinical 
or laboratory evidence of overt DIC.
Conclusions
Th e paradox remains that PCCs are eff ective because 
they increase the body’s ability to generate thrombin, 
while the total thrombin generation constitutes the 
primary safety concern with their use. Th e overall 
capacity to produce thrombin seems to be primarily 
associated with prothrombin levels. Th e use of PCCs in 
patients predisposed to thrombogenic complications 
makes it diffi  cult to determine whether thrombogenic 
events are attributable to or merely coincidental with 
PCC treatment. Th rombotic risk in patients without 
underlying risk appears to be fairly low with today’s 
PCCs. Changes to the production of PCCs, designed to 
address the possible causes of thrombogenic compli-
cations, have contributed to their improved safety. 
Th ese changes include the avoidance of activated 
factors, greater purity and a well-balanced content of 
clotting factors and inhibitors. However, additional 
factors that may contribute to thrombotic complications 
associated with PCC use remain to be elucidated. Th e 
putative benefi t of combined administration of PCCs 
with anti thrombin in high-risk patients such as those 
with liver insuffi  ciency or on VKA therapy is as yet 
unconfi rmed.
In patients with emergency bleeding, the risk of a 
thrombotic complication due to treatment with PCCs 
should be weighed against the need for rapid and 
eff ective correction of coagulopathy.
Sørensen et al. Critical Care 2011, 15:201 
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